MLSS Milestone Scientific, Inc.
Price Chart
Executive Summary
Milestone Scientific highlighted a new peer-reviewed study in Operative Neurosurgery showing that its CompuFlo Epidural System reduced composite complications by 91% during spinal cord stimulator implantation. The press release is promotional, citing growing clinical adoption but providing no new financial data or regulatory catalysts.
Actionable Insight
The study adds clinical evidence for CompuFlo's safety advantage, which could support gradual adoption in neuromodulation and pain management. However, without revenue data or a near-term catalyst, the stock is likely to trade on broader market sentiment and upcoming quarterly results. Monitor the next 10-Q for any revenue acceleration from increased procedure volumes.
Key Facts
- New study in Operative Neurosurgery from UTMB showed CompuFlo guidance associated with 91% reduction in odds of composite complications (CSF leak, blood patch, radiculopathy) in SCS procedures.
- CompuFlo has been evaluated or utilized across more than 40 universities, academic medical centers, and teaching hospitals worldwide.
- No financial data, revenue figures, earnings, or guidance were provided in the press release.
- The press release is a clinical adoption update, not a regulatory or financial event.
Financial Impact
No financial figures disclosed; clinical validation may support future adoption but near-term revenue impact is unquantifiable.
Risk Factors
- No financial data or guidance provided; the press release is purely promotional.
- Competitive pressure from other epidural access technologies and loss-of-resistance techniques.
- Milestone Scientific has a history of low revenue and cash burn; clinical adoption may not translate to near-term profitability.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301977 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
S-3
| $0.3900 $0.4340 | ▼ −11.28% | ▼ −10.88% | $0.3800 (+2.56%) |
|
May 27, 2026
13d ago
|
Press Release
| $0.3900 $0.4000 | ▲ +2.56% | ▲ +2.01% | $0.3800 (−2.56%) |
|
May 14, 2026
26d ago
|
Press Release
| $0.3400 $0.3300 | ▼ −2.94% | ▼ −1.71% | $0.3800 (+11.76%) |
|
May 6, 2026
4w ago
|
8-K
| $0.4700 $0.4600 | ▼ −2.13% | ▼ −2.96% | $0.3800 (−19.15%) |
|
May 6, 2026
4w ago
|
8-K
| $0.4700 $0.4600 | ▼ −2.13% | ▼ −2.96% | $0.3800 (−19.15%) |
|
Apr 21, 2026
7w ago
|
8-K
| $0.3200 $0.3400 | ▲ +6.25% | ▲ +5.23% | $0.3800 (+18.75%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $0.3200 $0.3400 | ▲ +6.25% | ▲ +5.23% | $0.3800 (+18.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access